LEADER 03321nam  22005535  450 
001 9910380726603321
005 20200702042916.0
010   $a3-030-37173-5
024 7 $a10.1007/978-3-030-37173-9
035   $a(CKB)4100000010480432
035   $a(DE-He213)978-3-030-37173-9
035   $a(MiAaPQ)EBC6126675
035   $a(PPN)242981771
035   $a(EXLCZ)994100000010480432
100   $a20200228d2020      u|             0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aNAFLD and NASH$b[electronic resource] $eBiomarkers in Detection, Diagnosis and Monitoring /$fedited by Manuel Romero-Gomez
205   $a1st ed. 2020.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2020.
215   $a1 online resource (X, 236 p. 18 illus., 17 illus. in color.) 
311   $a3-030-37172-7 
320   $aIncludes bibliographical references.
327   $aForeword -- Biochemical biomarkers of NAFLD/NASH -- MR based-Imaging Biomarkers in NAFLD/NASH -- Detection of NAFLD/NASH in general population -- Micro-vesicles in the diagnosis and monitoring of NASH -- Non-invasive biomarkers for monitoring NASH: NASH resolution and Fibrosis regression -- From transcriptome to proteomic in the development of biomarkers in NAFLD/NASH -- Transient elastography and ultrasound as imaging biomarkers in NAFLD/NASH -- Early detection of HCC in patients with NAFLD/NASH -- Genes and NAFLD/NASH progression -- Geometry of nutrition: micronutrients and NAFLD progression -- Psychological biomarkers profile in NAFLD/NASH with advanced fibrosis -- Integrative proposal of biomarkers use in clinical practice management of NAFLD/NASH.
330   $aThis book provides a comprehensive overview of the diagnosis and management of Non-alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatis (NASH). Basic principles of disease progression, the genetic and nutritional basis of NAFLD and NASH are explained along with the proteomic principles underlying biomarker development. Chapters cover both biochemical and imaging biomarkers used in elastrography and ultrasound and discuss how these are applicable to early diagnosis and monitoring of NASH and NAFLD. This is a useful resource for hepatologists, primary care providers with an interest in metabolic disease, diabetologists and endocrinologists in their daily clinical practice.
606   $aHepatology
606   $aEndocrinology 
606   $aMetabolism
606   $aHepatology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33088
606   $aEndocrinology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33053
606   $aMetabolomics$3https://scigraph.springernature.com/ontologies/product-market-codes/L15030
615  0$aHepatology.
615  0$aEndocrinology .
615  0$aMetabolism.
615 14$aHepatology.
615 24$aEndocrinology.
615 24$aMetabolomics.
676   $a610.28
702   $aRomero-Gomez$b Manuel$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910380726603321
996   $aNAFLD and NASH$92212337
997   $aUNINA